World Federation of Hemophilia/LinkedIn
Oct 30, 2025, 06:57
For People on Emicizumab, the Use of a aPCC Raises Critical Clinical Questions
World Federation of Hemophilia shared a post on LinkedIn:
“For people on emicizumab, the use of activated prothrombin complex concentrate (aPCC) raises critical clinical questions. A new article bridges evidence with real-world practice to guide safer, smarter care decisions.”
Title: Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice
Authors: Robert F. Sidonio, Jr., Guy Young, Carmen Escuriola Ettingshausen, Johnny Mahlangu, Margareth C. Ozelo, Alok Srivastava, Jerzy Windyga, Hye–Youn Lee, Aurelia Lelli, Steven W. Pipe
Read full article here.
Stay informed with Hemostasis Today.
activated prothrombin complex concentrate (aPCC)
Alok Srivastava
Aurelia Lelli
Carmen Escuriola Ettingshausen
Emicizumab
Guy Young
Health
Hematology
Hemostasis
Hemostasis Today
Hye–Youn Lee
Jerzy Windyga
Johnny Mahlangu
Jr.
Margareth C. Ozelo
Medicine
Robert F. Sidonio
rpth
Steven W. Pipe
World Federation of Hemophilia
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show